Minister, I've heard two things that, taken together, I think are cause for concern. One is that Canada has paid a relatively high price for access to these vaccines. Of course, it's hard to verify because we don't have access to the purchase agreements. The other is that one of the motivating factors for the European Union's recent move is that drug companies are withholding vaccine shipments to countries that have paid lower prices in order to send them to jurisdictions that are paying higher prices. That would put Canada, if you take those two things together, on a potential watch list for places that are receiving vaccine doses, given what we're paying.
I'm wondering if you can provide a little bit of insight into what Canada is paying compared with other countries and some reflections on whether Canada's signing up early at a high price means that it's on a potential watch list of exports to watch underneath this new European accountability mechanism.